Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $31.52, but opened at $35.28. Nanobiotix shares last traded at $35.1840, with a volume of 22,924 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NBTX. Guggenheim increased their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday. Finally, Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Stock Up 7.5%

The firm’s 50-day moving average is $24.96 and its 200 day moving average is $20.93.

Institutional Trading of Nanobiotix

Several institutional investors and hedge funds have recently modified their holdings of NBTX. Millennium Management LLC acquired a new stake in shares of Nanobiotix in the fourth quarter valued at approximately $390,000. Marshall Wace LLP acquired a new position in shares of Nanobiotix during the 4th quarter worth approximately $220,000. Optiver Holding B.V. purchased a new stake in Nanobiotix in the 3rd quarter valued at approximately $101,000. Finally, Royal Bank of Canada grew its holdings in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.